Bioresorbable stents make Cleveland Clinic’s Top 10 innovations for 2017
The Cleveland Clinic named bioresorbable stents as one of the top 10 medical innovations for 2017.
Michael Roizen, MD, the Cleveland Clinic’s chief wellness officer, led a group of more than 100 doctors and researchers who compiled the list. They announced the results Oct. 26 at the Cleveland Clinic’s Medical Innovation Summit.
The FDA approved the Absorb fully bioresorbable drug-eluting stent (Abbott) on July 5 to treat patients with coronary artery disease. No other bioresorable stents are FDA-approved, but other companies are manufacturing them. The Cleveland Clinic said the market for bioresorbable stents could reach $2 billion in six years.
Here is the list of 10 medical innovations to watch out for in 2017:
- Using the microbiome to prevent, diagnose and treat disease.
- Diabetes drugs that reduce cardiovascular disease and death.
- Cellular immunotherapy to treat leukemia and lymphomas.
- Liquid biopsies to find circulating tumor DNA.
- Automated car safety features and driverless capabilities.
- Fast healthcare interoperability resources.
- Ketamine for treatment-resistant depression.
- 3-D visualization and augmented reality for surgery.
- Self-administered HPV test.
- Bioresorbable stents.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.